Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone
Metabolic pathways regulate immune responses and disrupted metabolism leads to immune dysfunction and disease. Coronavirus disease 2019 (COVID-19) is driven by imbalanced immune responses, yet the role of immunometabolism in COVID-19 pathogenesis remains unclear. By investigating 87 patients with confirmed SARS-CoV-2 infection, 6 critically ill non-COVID-19 patients, and 47 uninfected controls, we found an immunometabolic dysregulation in patients with progressed COVID-19. Specifically, T cells, monocytes, and granulocytes exhibited increased mitochondrial mass, yet only T cells accumulated intracellular reactive oxygen species (ROS), were metabolically quiescent, and showed a disrupted mitochondrial architecture. During recovery, T cell ROS decreased to match the uninfected controls. Transcriptionally, T cells from severe/critical COVID-19 patients showed an induction of ROS-responsive genes as well as genes related to mitochondrial function and the basigin network. Basigin (CD147) ligands cyclophilin A and the SARS-CoV-2 spike protein triggered ROS production in T cells in vitro. In line with this, only PCR-positive patients showed increased ROS levels. Dexamethasone treatment resulted in a downregulation of ROS in vitro and T cells from dexamethasone-treated patients exhibited low ROS and basigin levels. This was reflected by changes in the transcriptional landscape. Our findings provide evidence of an immunometabolic dysregulation in COVID-19 that can be mitigated by dexamethasone treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
|---|---|
| Enthalten in: |
The Journal of clinical investigation - 131(2021), 22 vom: 15. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siska, Peter J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2021 Date Revised 16.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1172/JCI148225 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333171802 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333171802 | ||
| 003 | DE-627 | ||
| 005 | 20231225221111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI148225 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333171802 | ||
| 035 | |a (NLM)34779418 | ||
| 035 | |a (PII)e148225 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Siska, Peter J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2021 | ||
| 500 | |a Date Revised 16.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Metabolic pathways regulate immune responses and disrupted metabolism leads to immune dysfunction and disease. Coronavirus disease 2019 (COVID-19) is driven by imbalanced immune responses, yet the role of immunometabolism in COVID-19 pathogenesis remains unclear. By investigating 87 patients with confirmed SARS-CoV-2 infection, 6 critically ill non-COVID-19 patients, and 47 uninfected controls, we found an immunometabolic dysregulation in patients with progressed COVID-19. Specifically, T cells, monocytes, and granulocytes exhibited increased mitochondrial mass, yet only T cells accumulated intracellular reactive oxygen species (ROS), were metabolically quiescent, and showed a disrupted mitochondrial architecture. During recovery, T cell ROS decreased to match the uninfected controls. Transcriptionally, T cells from severe/critical COVID-19 patients showed an induction of ROS-responsive genes as well as genes related to mitochondrial function and the basigin network. Basigin (CD147) ligands cyclophilin A and the SARS-CoV-2 spike protein triggered ROS production in T cells in vitro. In line with this, only PCR-positive patients showed increased ROS levels. Dexamethasone treatment resulted in a downregulation of ROS in vitro and T cells from dexamethasone-treated patients exhibited low ROS and basigin levels. This was reflected by changes in the transcriptional landscape. Our findings provide evidence of an immunometabolic dysregulation in COVID-19 that can be mitigated by dexamethasone treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Metabolism | |
| 650 | 4 | |a Mitochondria | |
| 650 | 4 | |a Monocytes | |
| 650 | 4 | |a T cells | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Basigin |2 NLM | |
| 650 | 7 | |a 136894-56-9 |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Cyclophilin A |2 NLM | |
| 650 | 7 | |a EC 5.2.1.- |2 NLM | |
| 700 | 1 | |a Decking, Sonja-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Babl, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Matos, Carina |e verfasserin |4 aut | |
| 700 | 1 | |a Bruss, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a Klitzke, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Schön, Marian |e verfasserin |4 aut | |
| 700 | 1 | |a Simeth, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a Köstler, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Siegmund, Heiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ugele, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Paulus, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Dietl, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Kolodova, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Steines, Louisa |e verfasserin |4 aut | |
| 700 | 1 | |a Freitag, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Peuker, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Schönhammer, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Raithel, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Graf, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Geismann, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Lubnow, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Mack, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Hau, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Bohr, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Burkhardt, Ralph |e verfasserin |4 aut | |
| 700 | 1 | |a Gessner, Andre |e verfasserin |4 aut | |
| 700 | 1 | |a Salzberger, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Ralf |e verfasserin |4 aut | |
| 700 | 1 | |a Hanses, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Hitzenbichler, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Heudobler, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Lüke, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Pukrop, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Herr, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Wolff, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Spang, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Poeck, Hendrik |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Jantsch, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Brochhausen, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Lunz, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Rehli, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kreutz, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Renner, Kathrin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 131(2021), 22 vom: 15. Nov. |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2021 |g number:22 |g day:15 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI148225 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2021 |e 22 |b 15 |c 11 | ||